Indaptus Therapeutics (NASDAQ:INDP) Stock Price Up 2.9% – What’s Next?

Indaptus Therapeutics, Inc. (NASDAQ:INDP)’s stock price rose 2.9% during trading on Monday . The company traded as high as $0.48 and last traded at $0.48. Approximately 60,922 shares traded hands during trading, a decline of 57% from the average daily volume of 141,502 shares. The stock had previously closed at $0.46.

Indaptus Therapeutics Stock Up 2.9 %

The company’s 50 day simple moving average is $0.76 and its two-hundred day simple moving average is $0.98. The company has a market capitalization of $6.85 million, a price-to-earnings ratio of -0.28 and a beta of 1.62.

Indaptus Therapeutics (NASDAQ:INDP) last released its quarterly earnings results on Thursday, March 13th. The company reported ($0.38) EPS for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.03. Analysts anticipate that Indaptus Therapeutics, Inc. will post -1.79 EPS for the current year.

Indaptus Therapeutics Company Profile

Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial.